Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Male hypogonadism. Part I: Epidemiology of hypogonadism

International Journal of Impotence Research volume 18, pages 115–120 (2006)Cite this article

Abstract

Male hypogonadism is a frequent and potentially undertreated condition. A number of longitudinal epidemiologic studies, including the Baltimore Longitudinal Study of Aging, the New Mexico Aging Process Study, and the Massachusetts Male Aging Study, have demonstrated age-related increases in the likelihood of developing hypogonadism. In addition to advancing age, increasing body mass index and/or type II diabetes mellitus may be associated with lower circulating androgen levels. Owing to the demographic trends toward increasing population age and life expectancy, together with the emerging pandemic of diabetes and recent trend toward an increasing prevalence of obesity in the United States, clinicians are likely to encounter increasing cases of hypogonadism in the near future.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Food and Drug Administration. Skin patch replaces testosterone. In: Updates. Rockville, MD, Available at http://www.fda.gov/fdac/departs/196_upd.htm. Accessed September 27, 2004.

  2. US Census Bureau. US interim projections by age, sex, race, and Hispanic origin. 2004. Available at: http://www.census.gov/ipc/www/usinterimproj/. Accessed January 25, 2005.

  3. Batchelor WB, Jollis JG, Friesinger GC . The challenge of health care delivery to the elderly patient with cardiovascular disease: demographic, epidemiologic, fiscal, and health policy implications. Cardiol Clin 1999; 17: 1–15.

    Article  CAS  Google Scholar 

  4. Rhoden EL, Morgentaler A . Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med 2004; 350: 482–492.

    Article  CAS  Google Scholar 

  5. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR . Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2001; 86: 724–731.

    Article  CAS  Google Scholar 

  6. Morley JE, Kaiser FE, Perry III HM, Patrick P, Morley PM, Stauber PM et al. Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men. Metabolism 1997; 46: 410–413.

    Article  CAS  Google Scholar 

  7. Snyder PJ . Effects of age on testicular function and consequences of testosterone treatment. J Clin Endocrinol Metab 2001; 86: 2369–2372.

    CAS  PubMed  Google Scholar 

  8. Vermeulen A . Androgen replacement therapy in the aging male: a critical evaluation. J Clin Endocrinol Metab 2001; 86: 2380–2390.

    CAS  PubMed  Google Scholar 

  9. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB . Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151: 54–61.

    Article  CAS  Google Scholar 

  10. Bremner WJ, Vitiello MV, Prinz PN . Loss of circadian rhythmicity in blood testosterone levels with aging in normal men. J Clin Endocrinol Metab 1983; 56: 1278–1281.

    Article  CAS  Google Scholar 

  11. Selby C . Sex hormone binding globulin: origin, function and clinical significance. Ann Clin Biochem 1990; 27 (part 6): 532–541.

    Article  Google Scholar 

  12. Conway AJ, Handelsman DJ, Lording DW, Stuckey B, Zajac JD . Use, misuse and abuse of androgens: The Endocrine Society of Australia consensus guidelines for androgen prescribing. Med J Aust 2000; 172: 220–224.

    CAS  PubMed  Google Scholar 

  13. Dhindsa S, Prabhakar S, Sethi M, Bandyopadhyay A, Chaudhuri A, Dandona P . Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. J Clin Endocrinol Metab 2004; 89: 5462–5468.

    Article  CAS  Google Scholar 

  14. Muller M, den Tonkelaar I, Thijssen JH, Grobbee DE, van der Schouw YT . Endogenous sex hormones in men aged 40–80 years. Eur J Endocrinol 2003; 149: 583–589.

    Article  CAS  Google Scholar 

  15. International Diabetes Federation. Diabetes prevalence. Available at http://www.idf.org/home/index.cfm?node=264. Accessed January 28, 2005.

  16. Wolf AM, Colditz GA . Current estimates of the economic cost of obesity in the United States. Obes Res 1998; 6: 97–106.

    Article  CAS  Google Scholar 

  17. Ford ES, Giles WH, Dietz WH . Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356–359.

    Article  Google Scholar 

  18. Alexander CM, Landsman PB, Teutsch SM, Haffner SM . NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003; 52: 1210–1214.

    Article  CAS  Google Scholar 

  19. Tsai EC, Matsumoto AM, Fujimoto WY, Boyko EJ . Association of bioavailable, free, and total testosterone with insulin resistance: influence of sex hormone-binding globulin and body fat. Diabetes Care 2004; 27: 861–868.

    Article  CAS  Google Scholar 

  20. Haffner SM, Valdez RA, Stern MP, Katz MS . Obesity, body fat distribution and sex hormones in men. Int J Obes Relat Metab Disord 1993; 17: 643–649.

    CAS  PubMed  Google Scholar 

  21. Zumoff B, Strain GW, Miller LK, Rosner W, Senie R, Seres DS et al. Plasma free and non-sex-hormone-binding-globulin-bound testosterone are decreased in obese men in proportion to their degree of obesity. J Clin Endocrinol Metab 1990; 71: 929–931.

    Article  CAS  Google Scholar 

  22. Amatruda JM, Harman SM, Pourmotabbed G, Lockwood DH . Depressed plasma testosterone and fractional binding of testosterone in obese males. J Clin Endocrinol Metab 1978; 47: 268–271.

    Article  CAS  Google Scholar 

  23. Watanobe H, Hayakawa Y . Hypothalamic interleukin-1 beta and tumor necrosis factor-α, but not interleukin-6, mediate the endotoxin-induced suppression of the reproductive axis in rats. Endocrinology 2003; 144: 4868–4875.

    Article  CAS  Google Scholar 

  24. Russell SH, Small CJ, Stanley SA, Franks S, Ghatei MA, Bloom SR . The in vitro role of tumour necrosis factor-α and interleukin-6 in the hypothalamic-pituitary gonadal axis. J Neuroendocrinol 2001; 13: 296–301.

    Article  CAS  Google Scholar 

  25. Malkin CJ, Pugh PJ, Jones RD, Jones TH, Channer KS . Testosterone as a protective factor against atherosclerosis: immunomodulation and influence upon plaque development and stability. J Endocrinol 2003; 178: 373–380.

    Article  CAS  Google Scholar 

  26. Wang CA, Catlin DH, Demers LM, Starcevic B, Swerdloff RS . Measurement of total serum testosterone in adult men: comparison of current laboratory methods versus liquid chromatography-tandem mass spectrometry. J Clin Endocrinol Metab 2004; 89: 534–543.

    Article  CAS  Google Scholar 

  27. Larsen PR, Kronenberg HM, Melmed S, Polonsky K . Reference values. In: William's Textbook of Endocrinology 10th edn. WB Saunders: Philadelphia, PA, 2002.

    Google Scholar 

  28. Christ-Crain M, Meier C, Huber PR, Zimmerli L, Mueller B . Value of gonadotropin-releasing hormone testing in the differential diagnosis of androgen deficiency in elderly men. J Clin Endocrinol Metab 2005; 90: 1280–1286.

    Article  CAS  Google Scholar 

  29. Park K, Ku JH, Kim SW, Paick J-S . Risk factors in predicting a poor response to sildenafil citrate in elderly men with erectile dysfunction. BJU Int 2005; 95: 366–370.

    Article  Google Scholar 

  30. Lue TF, Giuliano F, Montorsi F, Rosen RC, Andersson K-E, Althof S et al. Summary of the recommendations on sexual dysfunctions in men. J Sex Med 2004; 1: 6–23.

    Article  Google Scholar 

  31. Taieb J, Mathian B, Millot F, Patricot M-C, Mathieu E, Queyrel N et al. Testosterone measured by 10 immunoassays and by isotope-dilution gas chromatography-mass spectrometry in sera from 116 men, women, and children. Clin Chem 2003; 49: 1381–1395.

    Article  CAS  Google Scholar 

  32. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients: 2002 update. Endocr Pract 2002; 8: 440–456.

  33. Snyder PJ . Hypogonadism in elderly men: what to do until the evidence comes. N Engl J Med 2004; 350: 440–442.

    Article  CAS  Google Scholar 

  34. Vaninetti S, Baccarelli A, Romoli R, Fanelli M, Faglia G, Spada A . Effect of aging on serum gonadotropin levels in healthy subjects and patients with nonfunctioning pituitary adenomas. Eur J Endocrinol 2000; 142: 144–149.

    Article  CAS  Google Scholar 

  35. Nanjee MN, Wheeler MJ . Plasma free testosterone: is an index sufficient? Ann Clin Biochem 1985; 22: 387–390.

    Article  Google Scholar 

  36. Vermeulen A . Testosterone in plasma: a physiopathological study. Verhandelingen – Koninklijke Academie voor Geneeskunde van Belgie 1973; 35: 95–180.

    CAS  PubMed  Google Scholar 

  37. Wilke TJ, Utley DJ . Total testosterone, free-androgen index, calculated free testosterone, and free testosterone by analog RIA compared in hirsute women and in otherwise-normal women with altered binding of sex-hormone-binding globulin. Clin Chem 1987; 33: 1372–1375.

    CAS  PubMed  Google Scholar 

  38. Morris PD, Malkin CJ, Channer KS, Jones TH . A mathematical comparison of techniques to predict biologically available testosterone in a cohort of 1072 men. Eur J Endocrinol 2003; 151: 241–249.

    Article  Google Scholar 

Download references

Acknowledgements

Financial disclosure: Series supported under an educational grant from Auxilium Pharmaceuticals. Dr Seftel has consulting relationships with Auxilium Pharmaceuticals, Bayer, Columbia Laboratories, Lilly ICOS LLC, Pfizer Inc., QLT Inc., and Sanofi-Synthelabo Inc., but no direct financial interest (eg stock ownership) in these companies.

Author information

Authors and Affiliations

  1. Department of Urology, Case Western Reserve University, University Hospitals of Cleveland, Cleveland, OH, USA

    A D Seftel

Authors
  1. A D Seftel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A D Seftel.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Seftel, A. Male hypogonadism. Part I: Epidemiology of hypogonadism. Int J Impot Res 18, 115–120 (2006). https://doi.org/10.1038/sj.ijir.3901397

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.ijir.3901397

Keywords

This article is cited by

Search

Advanced search

Quick links